We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
76
Beam Therapeutics
BEAM
$2.72B
$18.9M 0.29%
694,821
– –
TMO icon
77
Thermo Fisher Scientific
TMO
$196B
$18.8M 0.29%
35,342
-31,126
-47% -$15.1M
FATE icon
78
Fate Therapeutics
FATE
$324M
$18.1M 0.28%
4,851,579
– –
SILK
79
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$17.6M 0.27%
1,435,682
+5,120
+0.4% +$48K
VRNA
80
DELISTED
Verona Pharma
VRNA
$16.7M 0.26%
839,996
-16,362
-2% -$242K
TXG icon
81
10x Genomics
TXG
$5.48B
$16.4M 0.25%
293,173
-1,259
-0.4% -$54.8K
NTRA icon
82
Natera
NTRA
$38B
$16.1M 0.25%
256,584
-1,102
-0.4% -$55.1K
ESPR
83
DELISTED
Esperion Therapeutics
ESPR
$12.6M 0.19%
4,204,264
– –
LEGN icon
84
Legend Biotech
LEGN
$4.51B
$12.1M 0.19%
201,754
-76,400
-27% -$4.84M
AMGN icon
85
Amgen
AMGN
$197B
$9.85M 0.15%
34,205
-14,268
-29% -$3.89M
PHR icon
86
Phreesia
PHR
$659M
$9.76M 0.15%
421,573
-157,466
-27% -$2.72M
OM icon
87
Outset Medical
OM
$75.8M
$9.52M 0.15%
117,342
-43,220
-27% -$3.52M
REGN icon
88
Regeneron Pharmaceuticals
REGN
$70.8B
$9.41M 0.14%
10,709
-4,230
-28% -$3.48M
OMCL icon
89
Omnicell
OMCL
$2.05B
$8.42M 0.13%
223,816
-15,463
-6% -$569K
DOCS icon
90
Doximity
DOCS
$3.91B
$7.4M 0.11%
264,035
-135,422
-34% -$3.2M
ILMN icon
91
Illumina
ILMN
$28B
$6.26M 0.1%
46,253
-27,794
-38% -$3.21M
GBIO
92
DELISTED
Generation Bio
GBIO
$5.97M 0.09%
361,708
– –
TDOC icon
93
Teladoc Health
TDOC
$1.72B
$5.59M 0.09%
259,404
-96,245
-27% -$1.78M
RMD icon
94
ResMed
RMD
$28.7B
$5.22M 0.08%
30,320
-46,376
-60% -$7.13M
ONC
95
BeOne Medicines Ltd
ONC
$32.3B
$5.21M 0.08%
28,600
-24,600
-46% -$4.45M
JNJ icon
96
Johnson & Johnson
JNJ
$600B
$4.43M 0.07%
28,280
+5,457
+24% +$837K
NVRO
97
DELISTED
NEVRO CORP.
NVRO
$4.25M 0.07%
197,324
-847
-0.4% -$15.1K
RDY icon
98
Dr. Reddy's Laboratories
RDY
$10.5B
$4.24M 0.06%
304,500
-96,500
-24% -$1.29M
GILD icon
99
Gilead Sciences
GILD
$166B
$4.16M 0.06%
51,305
-56,045
-52% -$4.36M
MTEM
100
DELISTED
Molecular Templates, Inc.
MTEM
$3.84M 0.06%
1,029,820
-1,793
-0.2% -$9.38K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.